[Solved] What does MDMA do to the amygdala?

MDMA has a specific and profound effect on the amygdala, the brain region that regulates anxiety and emotional responses. During an MDMA session, the activity of the amygdala greatly reduced. This decreases the fear response, which is essential for processing emotionally charged memories or traumas.

This cushioning allows people to feel comfortable during therapy safe, open and connected feel. They dare to discuss topics that are normally too painful or frightening. This is one reason why MDMA has proven particularly effective in treating PTSD and other anxiety disorders.

In addition to this attenuation, MDMA stimulates the release of serotonin, dopamine and oxytocin - neurotransmitters that create feelings of well-being, confidence and empathy. This creates a temporary state where emotional processing is smoother and new insights about one's own behaviour and emotions emerge.

Emotions: empathy, euphoria and affective processing

Acute effects: MDMA is known for its strengthening positive emotions and social connectedness. After ingestion, a strong euphoria and cheerfulness, along with increased feelings of empathy and closeness to others. In controlled studies, subjects under the influence of MDMA report significantly improved mood and feelings of “bliss”. This euphoria is accompanied by increased release of monoamines (mainly serotonin, but also dopamine and noradrenaline) and hormones such as oxytocin, which promote prosocial behaviour and confidence. fMRI research shows that MDMA shifts the processing of emotional stimuli: it reduces the reactivity of the amygdala to negative facial expressions (e.g. angry faces), while attention and response to positive social cues are actually increased. For example, Bedi et al (2009) found that a single MDMA dose significantly reduced the response of the left amygdala in particular to angry faces compared to placebo. This may explain why MDMA users struggle to recognise negative emotions (such as anger or fear) in faces, while recognition of happy faces remains intact or even improves. At the same time, under MDMA, people actually experience more empathy: a meta-analysis of 6 placebo-controlled studies confirmed that MDMA invariably increased the emotional empathy of participants increases. In a direct comparison experiment, only the MDMA group (and not the control group with methylphenidate) showed more empathy for positive emotions in others and stronger subjective “empathogenic” feelings. Hysek et al. (2014) also reported that acute MDMA administration leads to less competitive behaviour and more empathetic caring in subjects. In summary, MDMA acutely creates an emotional state of increased positive affection (euphoria, feelings of love) and prosocial empathy, while negative affective stimuli are less pervasive.

Long-term effects: With moderate, occasional use of MDMA, there is as yet little evidence of lasting changes in emotional processing capacity. However, chronic or excessive MDMA use can lead to unwanted emotional consequences. Research suggests that heavy ecstasy users are more prone to mood disorders such as depression and anxiety when not under the influence. This is often attributed to neuroadaptation of the serotonergic system: long-term or high-frequency use can reduce serotonin transporters in the brain and deplete serotonin stores, resulting in a dip in mood after the acute drug phase. These users may experience a decrease in natural euphoria and general mood experienced and, in some cases, some flattening of affect or anhedonia. Moreover, clinicians report that heavy MDMA users sometimes have difficulty with emotional regulation and impulsivity, possibly related to serotonergic neurotoxicity. It is important to note that such long-term dysfunction is mainly associated with intensive use; at moderate dosage and low frequency of use no consistent long-term emotional disturbances have been demonstrated.

Anxiety regulation

Acute effects: MDMA has a notable anti-anxiety (anxiolytic) effect. Due to changes in amygdala activity MDMA reduces acute anxiety reactions to threatening stimuli. As mentioned above, under the influence of MDMA, the amygdala (the brain region responsible for detecting threat and initiating fear responses) becomes less active when seeing angry or threatening faces. This suggests that the automatic “alarm” function of the amygdala is temporarily muted. Indeed, fMRI has shown that MDMA reduces the limbic system (of which the amygdala is a part) becomes less active - an effect stronger in subjects who also subjectively felt the most relaxation and euphoria. Interestingly, at the same time, the connection between the amygdala (emotion centre) and the prefrontal cortex (higher control functions) becomes weaker under MDMA. This pattern - reduced limbic (amygdala) activity and decreased communication between emotion and control centres - is opposite to what is seen in anxiety disorders, where the amygdala is hyperactive and prefrontal control of anxiety is actually weakened. MDMA thus acutely induces a brain state associated with less anxiety and stress: subjects feel relaxed, socially open-minded and experience less fear of rejection or danger. Thus, MDMA has been found to suppress feelings of social threat and increase motivation to interact with others, partly because negative social cues (e.g. social disapproval) affect the user less strongly. Moreover, MDMA can simultaneously increase the sensitivity to positive stimuli increase, meaning that people respond more strongly to rewards and friendly faces than to threatening information. The net result is a state of increased confidence and reduced anxiety, which provides an important explanation for MDMA's prosocial effects.

Long-term effects: Although MDMA acutely reduces anxiety, the long-term effects are more complex. Repeated overuse of MDMA has been associated with increased baseline anxiety and irritability in some people. For example, animal studies show that rats weeks after a short MDMA exposure more anxious behaviour than control animals. This was associated with changes in serotonin receptors and transporters in the amygdala and hippocampus, among others. In humans, there is clinical evidence that heavy ecstasy users suffer more frequently from anxiety symptoms and panic attacks, which is in line with possible depletion of serotonergic neurotransmission. In other words, chronic MDMA abuse may make the amygdala more sensitive to stress in the absence of the drug, as the natural anxiety-inhibiting systems are depleted. However, it is important to distinguish between recreational abuse and therapeutic use: in controlled, occasional doses (as in MDMA-assisted therapy), no increase in chronic anxiety is usually seen - often rather the opposite, namely a lasting reduction in anxiety symptoms as traumas are better processed (see further under therapeutic implications). Nevertheless, researchers stress caution: MDMA should not be used frequently or unaccompanied because neurobiological adaptations by frequent use (e.g. downregulation of serotonin systems) can result in increased anxiety sensitivity in the long term.

Memory: emotional memory and trauma processing

Acute effects: MDMA affects the emotional memory in a unique way. On the one hand, MDMA is known to acutely disrupt short-term memory and working memory somewhat - users struggle to remember or process complex information during intoxication. More important in this context, however, are the effects on memories and trauma. Under the influence of MDMA, painful memories seem less overwhelming: in an experiment in which healthy volunteers recalled their most negative and most positive autobiographical memories under fMRI, after MDMA intake they rated their negative memories as less negative compared with placebo. At the same time, their positive memories fMRI scans showed that this coincided with altered activity in brain regions - parts of the brain were less strongly activated under MDMA than under placebo when reliving the “worst” memories. Dr Carhart-Harris, who led this study, noted that MDMA “seems to soften the impact of painful memories” and allows people to think back on trauma without being overwhelmed by negative emotions. This supports the hypothesis that MDMA is a therapeutic window opens in which traumatic memories can be revisited with less anxiety. Neuroscientifically, MDMA possibly promotes processes such as fear extinction (extinction of fear memory) and memory reconsolidation (renewed storage of memories in modified form). Indeed, animal and human studies have given indications that MDMA increases the reconsolidation of fear memories can disrupt or weaken, and the extinction of fear can facilitate. This means that when someone retrieves a traumatic memory under MDMA, the memory may be “rewritten” in the brain with a lower emotional charge, reducing the fear response in subsequent memories. MDMA also acutely increases the functional connectivity between the amygdala and hippocampus (memory centre). Normally in PTSD patients, we actually see impaired communication between amygdala and hippocampus, which is associated with poor contextual processing of fear memories. MDMA (temporarily) restores this communication, which could mean that emotional memories are better contextualised and processed. All these acute effects - reduced anxiety, modified emotional labelling of memories, and increased connection between emotion and memory centres - contribute to MDMA being a favourable environment for trauma treatment creates.

Long-term effects: When it comes to long-term effects of MDMA on memory, we need to distinguish between neurotoxicity from abuse and therapeutic use effect. Studies in chronic ecstasy users show that they have measurable memory problems may develop. In particular, verbal memory and working memory may perform worse in heavy users than in non-users, possibly due to serotonin damage in hippocampus and cortex. In animal experiments, high doses of MDMA led to a significant decrease in serotonin in the hippocampus and amygdala and up- or downregulation of serotonin receptors, without a complete death of neurons in these areas. These changes were accompanied by long-term behavioural changes, including reduced memory and increased anxiety. In human users, evidence for irreversible memory impairment is less unequivocal; some studies signal mild cognitive decline (such as difficulty learning new information or remembering complex tasks) in intense users, while other factors (such as poly-drug use or pre-existing differences) may also explain this. In contrast, therapeutic applications of MDMA (sporadically, in a controlled setting) actually has the opposite effect on trauma-related memory: patients can remember their trauma without intense emotional reaction and afterwards the trauma is often perceived as less intrusive. Importantly, in clinical settings, doses and frequency are very limited, minimising neurotoxicity. In summary: excessive recreational use of MDMA can impair memory, while supervised therapeutic use can actually “reset” or restructure emotional memory in a way that is healing for trauma.

Structural and functional changes in the amygdala

Acute effects (fMRI and neurobiological): MDMA causes clear functional changes in the amygdala and related structures during acute intoxication. Brain-imaging studies show a decrease in activity and blood flow of the amygdala under the influence of MDMA. With arterial spin labelling (ASL) fMRI, for example, has been shown that MDMA increases the cerebral blood flow (CBF) in the right medial temporal lobe (including the amygdala) is significantly reduced. This reduced activity is not diffuse across the brain, but occurs specifically in emotion- and memory-related areas (amygdala, hippocampus, limbic cortex), combined with increased activity in reward areas. Interestingly, the degree of CBF decrease in the amygdala and hippocampus correlates with the intensity of the subjective MDMA experience (the stronger a person feels the effect, the more decrease in amygdala activity). At the same time, one sees changes in the functional connectivity: MDMA increases the intercommunication between the amygdala and hippocampus (indicating greater synchronisation between emotion and memory processing) and reduces connectivity between the medial prefrontal cortex and both the amygdala/hippocampus and the posterior cingulate cortex. This means that during MDMA administration, the “top-down” influences of control regions on the amygdala decrease, while the “mutual dialogue” between amygdala and memory centres increases. Figure 1 illustrates this: blue areas indicate decreased activity in limbic structures during acute MDMA ingestion. Figure 1: fMRI scans show that MDMA reduces blood flow (and thus activity) in limbic brain areas, including the amygdala (blue highlighted areas). This reduction in activity of emotion-processing centres correlates with subjective drug experience (such as feelings of calmness and euphoria). Besides blood flow and connectivity, neurochemistry in the amygdala also changes acutely: MDMA floods this area with serotonin. The amygdala is rich in serotonin receptors, and acute overstimulation of these can directly suppress the activity of amygdala neurons. In addition, MDMA stimulates the release of oxytocin via the hypothalamus; oxytocin is known to reduce amygdala reactivity to social threat. Together, these acute changes lead to a “Softening” of amygdala function - less fear, more social openness - during the drug's duration of action.

Long-term effects (structural): The question of whether MDMA causes lasting structural changes in the amygdala has been carefully investigated. Moderate MDMA use (occasional intermittent use) does not appear to cause permanent damage or volume change in the amygdala; a systematic review found no convincing evidence for structural brain abnormalities in recreational users with low-to-moderate consumption. In contrast, chronic heavy use trigger certain subtle changes. Although conventional MRI scans rarely show clear lesions or volume loss in the amygdala in MDMA users, post-mortem and animal studies have documented neurochemical changes. For instance, a rat study showed that high doses of MDMA induced long-term decrease in serotonin and 5-HIAA levels in the amygdala induced, indicating damage to serotonergic axon terminals in this area. Moreover, a reduction in serotonin transporter proteins was observed after repeated exposure. In human PET scanning studies, reduced binding of serotonin transporters in different brain regions have been reported in heavy ecstasy users, consistent with these findings of serotonin neurotoxicity. Structural MRI also shows reduced grey matter volumes in certain frontal and temporal regions in some heavy users, although the evidence for this is inconclusive and polydrug use may play a role. For the amygdala specifically, volumetric changes are difficult to establish; some PTSD studies show a reduced amygdala in chronic stress, but this has not been consistently demonstrated in MDMA users. However, it is plausible that microstructural changes - such as changes in dendrites, synaptic density or glial cells - occur during prolonged overstimulation and depletion of neurotransmitters, although these are subtle. Furthermore, tolerance development an indication of neuroadaptation: users find that with frequent MDMA use, the empathogenic effect decreases and they need higher doses for the same effect, which is related to downregulation of serotonin receptors and transporters. In summary, functional changes (such as altered activity and connectivity) under MDMA clear and reproducible, while structural damage to the amygdala in human use is mainly a risk with long-term, excessive use and then mainly visible in terms of neurochemical modifications (loss of serotonin innervation) rather than drastic volume reduction.

Therapeutic implications: MDMA and PTSD treatment

MDMA's unique effects on emotion, anxiety and memory have led to much interest in MDMA-assisted psychotherapy, especially for post-traumatic stress disorder (PTSD). PTSD is characterised by a hyperactive amygdala (excessive fear responses, hypervigilance) and incompletely processed trauma memories that cause recurrent nightmares and flashbacks. MDMA has exactly those properties that can support therapy for PTSD: the drug dampens fear response (due to amygdala suppression) and strengthens positive emotions and empathy, making patients feel safe and connected to the therapist. Also, MDMA seems to put the brain into a plastic state in which fear extinction and trauma processing can take place optimally. During MDMA sessions, PTSD patients can often speak about their trauma with unprecedented clarity without being overwhelmed by panic. This allows them to revisit and reappraise memories in the presence of a therapist, leading to re-storage of the trauma with less emotional charge. Moreover, MDMA promotes strong therapeutic alliance: due to the increase in empathy and trust, patients feel understood and supported, and therapists find that patients are more open about their feelings. This combination of reduced anxiety, increased emotional processing and improved alliance has resulted in remarkably positive clinical outcomes.

In clinical trials in PTSD, MDMA-assisted therapy has shown extraordinary results. In randomised double-blind studies, chronic PTSD patients received a few (usually 2-3) therapy sessions with MDMA (versus placebo therapy in the control group). After completion, about 67-71% of the patients in the MDMA group no longer met the PTSD diagnosis, compared with about 21-47% in the placebo group. In other words, two-thirds to three-quarters of PTSD patients were clinically recovered or significantly improved after MDMA therapy, compared with a much smaller fraction with usual therapy alone. The symptom score (CAPS-5) decreased significantly in the MDMA group compared to placebo, and functional limitations (anxiety in daily life) improved significantly. Moreover, these effects were found to durable: in follow-ups months later, a large proportion of MDMA-treated patients maintained their improved condition. No serious side effects were reported; MDMA therapy under medical supervision was considered safe and well tolerated assessed, with temporary side effects (such as tense jaw, sweating, mild heart rate and blood pressure rise) that went away on their own.

The therapeutic implications may extend beyond PTSD. Since MDMA has prosocial and anxiety-inhibiting effects, it is being investigated whether it could help with other conditions involving social functioning or trauma. For instance, a small study in autistic adults with social anxiety showed that MDMA-assisted therapy could greatly reduce social anxiety. Occasional experiments with MDMA-assisted support are also being conducted in terminal cancer patients (existential anxiety) and people with treatment-resistant depression. However, the most important and farthest-researched domain remains PTSD, where MDMA has now successfully completed phase-3 clinical trials and is likely on its way to regular approval as a adjuvant treatment in therapy-resistant PTSD. The positive effects can be directly linked to MDMA's influence on the amygdala and related circuits: by the turning off the “fear switch” (amygdala) and the switching on “safety and connectedness mode” therapy that was previously too difficult - such as reliving trauma - can suddenly take place. This insight represents a paradigm shift in psychiatry: instead of suppressing fear memories with daily medication, one uses a few targeted MDMA sessions to address the core of trauma in the brain, partly by temporarily quieting the amygdala.

Conclusion

MDMA exerts powerful effects on the amygdala and the brain's emotion networks, both acutely and (with intensive use) chronically. Shortly after administration, we see a decrease in amygdala activity and a shift towards positive emotional processing: users experience euphoria, empathy and reduced anxiety, partly because the amygdala signals threat less strongly. This acute “amygdala-dampening” effect underlies MDMA's prosocial and therapeutic properties. In the long term, the effects are twofold: at therapeutic use MDMA can provide lasting improvement in anxiety- and trauma-related symptoms (thanks to facilitating emotional processing), while chronic abuse can lead to neurobiological adaptations (especially in the serotonin system) that actually negatively affect anxiety and mood. Structural damage to the amygdala has not been shown in sparing use, but very high use can partially deplete serotonin neurons in limbic areas like the amygdala.

All in all, findings from neurobiological and clinical research confirm that MDMA “recalibrates” the amygdala, so to speak: temporarily less fear and more social emotion, offering unique opportunities for treatment of stress- and trauma-related disorders. At the same time, these effects underline the importance of respectful and moderated use, as the fragile amygdala system can become unbalanced if misused. MDMA's impact on the amygdala - from increasing empathy and ecstasy to relieving deep-seated anxiety - illustrates how one substance can both exciting therapeutic perspectives can open as warnings for prudent use, depending on context and dosage.

Want to delve deeper into how MDMA therapy works and whether it's right for you? Then check out the detailed explanation on the page MDMA therapy.